Cagrilintide: Research, Dosing, and Where to Buy in 2026
A research-first profile for Cagrilintide, aggregating mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature without presenting medical guidance.
Cagrilintide is a research compound profiled here from named-expert transcripts and peer-reviewed literature, without medical guidance. As of July 2026, The Peptide Wiki aggregates 15 PubMed-cited papers, 3 attributed expert mentions, and 2 transcript dosing protocols for Cagrilintide, each linked to its source.
- 2 aggregated dosing-protocol mentions from source transcripts.
- 15 PubMed-indexed citations listed in the research table below.
- 0 vendor recommendations captured from named experts.
- Evidence level in this entry is marked as anecdotal.
What is Cagrilintide?
Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.
Experts on background and overview · 1 cited mention
"cagrolintide was a no-go for me. Even in a low dose of half a milligram three times a week on top of I think 1 mg retatrutide"
What is Cagrilintide researched for?
Amylin analog; reported to cause lethargy when used by Nile.
Cagrilintide Dosing Protocols
The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.
| Speaker | Source | Timestamp | Protocol | Evidence |
|---|---|---|---|---|
| Vigorous Steve | Staying Dry On A Cut, Injectable Oral AAS, Sleep: GH Secretagogues... | 00:12:40 | Vigorous Steve reported using 0.5 mg cagrilintide three times per week on top of retatrutide, and reported lethargy, increased hunger, and nausea before abandoning the protocol (anecdotal, source: zKQowBZmg7U). | anecdotal |
| Vigorous Steve | BAM15 Vs. ATX-304, Cagrilintide Vs. Eloralintide, SLU-PP-915,... | 00:24:45 | Vigorous Steve reported suggesting an amylin agonist range: start low and escalate; roughly 1-2 mg amylin receptor agonist compared with 2-10 mg GLP-1 depending on tolerance and half-life. | anecdotal |
Where to Buy Cagrilintide in 2026
No tracked vendor recommendations for Cagrilintide yet. See our vendor directory.
Side Effects and Safety
Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.
Experts on side effects and safety · 1 cited mention
"I tried keg girlite and that made me feel lethargic as hell. Man, I just ended up eating more to get some energy"
What Experts Say
2 experts across our source library discuss Cagrilintide. Each entry is that expert’s most context-rich mention: click to watch it at the exact timestamp in the original video. Quotes are also emitted as Schema.org Quotation JSON-LD for AI assistants.
-
“cagrolintide was a no-go for me. Even in a low dose of half a milligram three times a week on top of I think 1 mg retatrutide”
-
“I tried keg girlite and that made me feel lethargic as hell. Man, I just ended up eating more to get some energy”
User Reviews
User reviews aggregator coming Q3 2026 (Reddit + YouTube comments + Discord research notes). Until then, see the expert quote section above and PubMed citations below.
Research Efficacy Snapshot
Published efficacy percentages cited in PubMed trials and named-expert reports about Cagrilintide. Each line links to the original source.
- "Cagrilintide significantly reduced percent body weight versus placebo (mean difference - 6.08%, 95% CI - 8.02 to - 4.14), as did CagriSema (- 5.98%, 95% CI - 10.64 to - 1.32)." · Rao H et al, 2026 PubMed
- "226 (68%) participants were male and 105 (32%) were female; 80 (24%) had type 2 diabetes." · Yamauchi T et al, 2026 PubMed
- "17 (10%) participants discontinued cagrilintide-semaglutide and ten (6%) discontinued semaglutide." · Yamauchi T et al, 2026 PubMed
- "The estimated mean change in bodyweight from baseline to week 68 was -18·4% (SE 0·7) in the cagrilintide-semaglutide group versus -11·9% (0·7) in the semaglutide group (estimated treatment difference [ETD] -6·5 percentage points [95% CI -8·4 to -4·6]; p<0·0001)." · Yamauchi T et al, 2026 PubMed
- "Adverse events were reported by 143 (87%) of 164 participants in the cagrilintide-semaglutide group and 141 (84%) of 167 in the semaglutide group, the most common of which were gastrointestinal disorders (87 [53%] of 164 participants in the cagrilintide-semaglutide group vs 85 [51%] of 167 in the semaglutide group)." · Yamauchi T et al, 2026 PubMed
- "Multi-receptor agonists represent the most transformative developments: triple agonists such as retatrutide achieve weight reductions of 20-24%, while dual GLP-1/glucagon agonists like survodutide and mazdutide show strong efficacy with particular promise for metabolic-associated steatotic liver disease." · Lempesis IG et al, 2026 PubMed
- "The amylin pathway has re-emerged through long-acting analogs (cagrilintide, eloralintide) and unimolecular co-agonists (amycretin), achieving weight reductions up to 24% via distinct neuroendocrine circuits." · Lempesis IG et al, 2026 PubMed
- "According to World Health Organization (WHO) 2016, 40% of adults are overweight and 13% are obese, highlighting obesity's persistence throughout life." · Mishra NK et al, 2026 PubMed
- "**RESULTS**: Palmitic acid (PA) significantly impaired mitochondrial function, reducing basal oxygen consumption rate (OCR) by 22% (p = 0.0056) and ATP production by 25% (p = 0.0022)." · Old V et al, 2026 PubMed
- "In healthy myotubes, semaglutide and cagrilintide transiently reduced basal respiration (↓21%-28%, p < 0.05) and ATP production (↓24%-31%, p < 0.01) at 48 h, along with reductions in Complexes I, III and IV protein expression, all of which resolved by 5 days." · Old V et al, 2026 PubMed
Research and Studies
15 PubMed-indexed papers reference Cagrilintide. Top 15 shown.
Legal Status
Cagrilintide is presented here as a research compound. FDA approval status, scheduling, WADA status, and state-specific telehealth rules may apply. Always verify current regulatory status. Last verified: 2026-07-09.
Frequently Asked Questions
Is Cagrilintide FDA-approved?
Cagrilintide is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.
What dosing is reported for Cagrilintide?
This page aggregates 2 dosing-protocol mention(s) from named-expert transcripts, each linked to a verbatim source timestamp. See the Dosing Protocols table above. Mentions are anecdotal, not medical advice.
How much research has been published on Cagrilintide?
15 PubMed-indexed paper(s) reference Cagrilintide in our current research feed. See the Research and Studies section above for citations.